Catalyst Dossier · compiled by CeliA 🧫

4D pharma plc (FOUR.L)

Services-Business Services, NEC · market cap $3.1B · as of 2026-06-29

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

The facts provided describe Shift4 Payments, Inc. (a U.S. payment processing company), not 4D Pharma plc (FOUR.L), a UK-listed live biotherapeutics company. The structured data contains a fundamental mismatch: company description, sector, and financials belong to Shift4, while the pipeline entry references Blautix, a live biotherapeutic developed by 4D Pharma for Irritable Bowel Syndrome. Because the underlying data is internally contradictory and critical fields (cash, runway, financials, share price, mechanism of action) are absent, this dossier is materially incomplete.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Blautix	Phase 2	Irritable Bowel Syndrome

Price & technical context

3-month

+20.4%

6-month

+9.6%

12-month

-21.3%

52-wk range

$3035.00–$6030.00

vs 50-day MA

+8.4%

vs 200-day MA

+8.2%

Realized vol

43.6%

Max drawdown

-53.6%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for FOUR.L (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.